These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 29500862)

  • 1. Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.
    Tsitsikov E; Harris MH; Silverman LB; Sallan SE; Weinberg OK
    Int J Lab Hematol; 2018 Jun; 40(3):343-351. PubMed ID: 29500862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Easy discrimination of hematogones from lymphoblasts in B-cell progenitor acute lymphoblastic leukemia patients using CD81/CD58 expression ratio.
    Nagant C; Casula D; Janssens A; Nguyen VTP; Cantinieaux B
    Int J Lab Hematol; 2018 Dec; 40(6):734-739. PubMed ID: 30113764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
    Baraka A; Sherief LM; Kamal NM; Shorbagy SE
    Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.
    Thulasi Raman R; Anurekha M; Lakshman V; Balasubramaniam R; Ramya U; Revathi R
    Leuk Lymphoma; 2020 Aug; 61(8):1974-1980. PubMed ID: 32281503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
    Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
    Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Application of effective antigen combinations in childhood B lineage acute lymphoblastic leukemia].
    Liu Y; Tang JY; Xu C; Gu LJ; Xue HL; Chen J; Pan C; Dong L; Zhou M
    Zhonghua Er Ke Za Zhi; 2009 May; 47(5):366-70. PubMed ID: 19573409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
    Arumugam JR; Bommannan K; Radhakrishnan V; Sagar TG; Sundersingh S
    Leuk Lymphoma; 2022 Mar; 63(3):644-652. PubMed ID: 34727819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
    Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.
    Patkar N; Alex AA; B B; Ahmed R; Abraham A; George B; Vishwabandya A; Srivastava A; Mathews V
    Cytometry B Clin Cytom; 2012 Jul; 82(4):252-8. PubMed ID: 22467604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
    Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Recognition of Hematogones From Precursor B-Lymphoblastic Leukemia by a Single Tube Flow Cytometric Analysis.
    Don MD; Lim W; Lo A; Cox B; Huang Q; Kitahara S; Lopategui J; Alkan S
    Am J Clin Pathol; 2020 May; 153(6):790-798. PubMed ID: 32068791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Verbeek MWC; van der Velden VHJ
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.
    Lúcio P; Parreira A; van den Beemd MW; van Lochem EG; van Wering ER; Baars E; Porwit-MacDonald A; Bjorklund E; Gaipa G; Biondi A; Orfao A; Janossy G; van Dongen JJ; San Miguel JF
    Leukemia; 1999 Mar; 13(3):419-27. PubMed ID: 10086733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
    Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunophenotypic portrait of leukemia-associated-phenotype markers in B acute lymphoblastic leukemia.
    Boris E; Theron A; Montagnon V; Rouquier N; Almeras M; Moreaux J; Bret C
    Cytometry B Clin Cytom; 2024 Jan; 106(1):45-57. PubMed ID: 38037221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia].
    Pawińska-Wasikowska K; Balwierz W
    Przegl Lek; 2010; 67(6):361-5. PubMed ID: 21344762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
    Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
    Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.
    Xiao W; Salem D; McCoy CS; Lee D; Shah NN; Stetler-Stevenson M; Yuan CM
    Cytometry B Clin Cytom; 2018 May; 94(3):434-443. PubMed ID: 28888074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.